New Jobs
Nurse Innovators Take the Spotlight at ViVE 2025 Holland startup raises $27M to expand gig-based medical coding platform Omnicare Pharmacy to Pay $124M Settlement for Illegal Kickbacks to Nursing Homes State scholarship aims to address behavioral health worker shortage - YouTube Omnicare Pharmacy to Pay $124M Settlement for Illegal Kickbacks to Nursing Homes Night Nurse Arrested For Not Feeding Child, Faces Felony Neglect Charges - Nurse.org Wallace-Dothan hosts simulation for area nursing and medical students - MSN Baystate Health eliminates nearly 100 corporate positions | HealthLeaders Media This Week's Health IT Jobs – February 5, 2025 | Healthcare IT Today Fake Nurse Sentenced for Medicaid Fraud, Gets 5 Years Probation - Nurse.org (Dual post linked with Job ID 54730 Medical Coding Specialist) - HigherEdJobs The new-collar revolution - The New Indian Express PMBAUSA LLC Grants $2M Worth of Medical Coding Credentials as Part of Certification ... JCC partners with CareerStep for online healthcare job training | News | bradfordera.com ScribeEMR to Highlight AI Scribing and Virtual Coding Advances at the National Association ..... CAPS launches new program for lab techs - The Source - WashU American Nurses Association Announces Code of Ethics for Nurses Revision 2025 Intermediate Full Stack C# Developer - South Africa - Centurion - Bizcommunity This Week's Health IT Jobs – January 29, 2025 | Healthcare IT Today Peirce College to Work with Chester County Economic Development Council on Good Jobs ... - MS... Opening Up About My Mental Health, How a Wellness Retreat Helped Me Overcome Past Trauma Per Diem Nurse Staffing Market to Skyrocket—$16.4 Billion by 2033 - Nurse.org Medical Coding Market Size to Surpass USD 89.49 Billion by 2033 | Straits Research Peirce College to Work with Chester County Economic Development Council on Good Jobs ... AI job market booms with 42% growth over two years; overall hiring up by 31% (YoY) in Decembe... Nurse Practitioner Billed Insurance $62M In Fake B-12 Shots Scheme, Gets 5 Years Prison High-Paying Jobs That Don't Require College Salary Story: I Never Thought I Would Make Six Figures — Here's How I Got There - MSN Unifying Innovation and Patient-Centricity: Clinion Leads the AI Revolution at ISCR 2025 Offered $45 and Hour With a Master's Degree - Nurse Educator Pay Is a Healthcare Crisis VA Hospital Overhauls Security After Nurse Attack U.S. News and World Report Best Jobs - MedCentral Top 10 Highest-Paying Remote Jobs in 2025 - Education Times Zuckerberg Announces Plans to Automate Facebook Coding Jobs With AI - MSN Incentives aim to lure RNs to nursing home jobs | HealthLeaders Media Top Master's in Health Informatics Programs | 2025 - Nurse.org Get paid +$150,000 in 2025: 5 remote jobs to travel the world - ECOticias.com Nearly One-third of Nursing Assistants Are Immigrants In MN - Here's Why - Nurse.org Solutions3X Opens Medical Coding Center in Hyderabad - Business News This Week Hyderabad: Skill University announces 3 new courses YIS University rolls out 3 job-oriented courses - The Hans India Solutions3X opens medical coding training centre in Ameerpet, second unit in city Ambulance Billing Technician | Jobs | uniondemocrat.com Meet the Monster Truck-Driving ER Nurse! Medical Record Technician (Coder) Job in Naytahwaush, Minnesota - LemonWire 24 Useless College Degrees Facing Dead-End Jobs and Loads of Debt - MSN 24 Useless College Degrees Facing Dead-End Jobs and Loads of Debt - MSN Artificial Intelligence and Its Impact on the Job Market - Techshali MPESB Group 4 Salary 2025: Post-wise Job Profile, Pay Scale, Benefits & Yearly Package Top 5 Work-From-Home Nurse Practitioner Jobs for 2025

Medical Coding Jobs

Find your dream Job in Medical Coding

Medical Coding Jobs
News

The Hype Has Faded, but Don’t Count Out Convalescent Plasma in Covid Battle

Six months after it was controversially hailed by Trump administration officials as a “breakthrough” therapy to fight the worst effects of covid-19, convalescent plasma appears to be on the ropes.

This story also ran on NBC News. It can be republished for free.

The treatment that infuses blood plasma from recovered covid patients into people newly infected in hopes of boosting their immune response has not lived up to early hype. Some high-profile clinical trials have shown disappointing results. Demand from hospitals for the antibody-rich plasma has plunged. After a year of large-scale national efforts to recruit recovered covid patients as donors and the collection of more than 500,000 units of covid convalescent plasma, known as CCP, some longtime advocates of the therapy say they’re now pessimistic about its future.

“I fear the CCP train has left the station,” said Dr. Michael Busch, director of the Vitalant Research Institute, one of the largest blood-center based transfusion medicine research programs in the U.S. “We created all this enthusiasm, and then these studies came out and they say this stuff didn’t work in the first place.”

But that sentiment is by no means universal. Other respected proponents say we are watching the science progress in real time, and it’s simply too soon to count out convalescent plasma. They note that larger studies employing more calibrated doses of convalescent plasma and more targeted groups of patients, during a set window in their illness, have met the standards for moving forward and may show promise.

“It’s just been a really interesting story to see it unfold,” said Dr. Julie Katz Karp, director of transfusion medicine at Thomas Jefferson University Hospitals in Philadelphia. “People are doing a good job of reading the literature, but one week the answer is ‘yes,’ the next week, ‘maybe not.’”

Convalescent plasma was thrust into the national conversation last August, when the Food and Drug Administration, under political pressure, made the decision to authorize the treatment for emergency use despite objections from federal government scientists cautioning that the therapy was unproven. In the months since, tens of thousands of Americans have been infused with plasma.

Enthusiasm faded in recent weeks following two serious setbacks: A large federal clinical trial, dubbed C3PO, testing the use of convalescent plasma in high-risk patients who came to an emergency room with mild to moderate covid symptoms was halted late last month after researchers concluded that, while the infusions caused no harm, they were unlikely to benefit patients. That same week, a pooled analysis of 10 convalescent plasma studies, published in JAMA, found no clear benefit.

In January, the FDA scaled back the emergency authorization of convalescent plasma, limiting its use to hospitalized covid patients early in the course of the disease and those with medical conditions that impair immune function. The agency also said that only plasma with high concentrations of virus-fighting antibodies could be used after May 31.

At the same time, the covid surge that engulfed the U.S. through much of the winter eased, sending demand for convalescent plasma plummeting. Hospital infusions fell from a high of about 30,000 units a week at the start of the year to about 7,000 per week in early March.

Further complicating matters, federal contracts worth $646 million that paid U.S. blood centers to collect covid convalescent plasma are about to expire, prompting centers nationwide to reconsider whether the complicated process of collecting the plasma is still worth the work. Given the added complexity, blood centers have been reimbursed $600 to $800 a unit for the covid product, compared with the $100 price for a regular unit of fresh, frozen plasma.

“We’re not getting orders,” said Dr. Louis Katz, chief medical officer at the Mississippi Valley Regional Blood Center in Davenport, Iowa. “I don’t want to collect a product that is not going to get used and will cost me more money.”

Officials with the American Red Cross have paused direct collection of convalescent plasma, citing changes required by the FDA’s revised emergency use authorization and an “evolving” market. People previously infected with covid may still donate whole blood, and those units that test positive for high levels of antibodies could be used as CCP.

Even as they acknowledge the setbacks, plasma proponents say declaring its death just a few months into the research would be a foolish overreach. The idea of using plasma from recovered patients to treat the newly ill is a century-old concept that has been employed on an experimental basis during a host of plagues, including the devastating 1918 flu, the 1930s measles outbreak and, more recently, Ebola.

Rather than abandon efforts, scientists need to refine the way convalescent plasma is used and temper their expectations, said Dr. Michael Joyner, principal investigator of the Mayo Clinic-led program that supplied convalescent plasma for more than 100,000 U.S. patients last year.

“This is an unstandardized dose of an unstandardized product being given to all comer patients for a disease with variable progression,” Joyner said in an email. “So it is unrealistic to expect cookie-cutter results like you get for statin/heart attack trials.”

Joyner and others pointed to research that continues to show promise. In mid-February, scientists in Argentina reported that giving convalescent plasma with very high concentrations of antibodies within three days of onset of mild covid symptoms helped slow the progression of disease in older patients. In mid-March, researchers in the U.S. and Brazil reported in a study that has not yet been peer-reviewed that plasma therapy didn’t improve symptoms during hospitalization for patients with severe cases of covid. But it was associated with a 50% reduction in death after 28 days that “may warrant further evaluation,” the authors wrote.

Oversight committees this month gave the nod to two federally funded clinical trials of convalescent plasma to continue enrolling hundreds of patients. One, led by researchers at Johns Hopkins University, is testing convalescent plasma in people who were infected and developed symptoms of covid but were not hospitalized. The other, led by scientists at Vanderbilt University, is testing high-potency plasma in hospitalized patients.

There’s no question “antibodies work against the virus,” said Dr. David Sullivan, a professor of molecular microbiology and immunology at Johns Hopkins University and a principal investigator for the institution’s plasma trials.

“It’s all dose and time,” Sullivan said, adding that giving convalescent plasma with high concentrations of antibodies within the first few days of infection is crucial.

The most promising use of convalescent plasma might come from “super donors,” people who were infected with covid and then vaccinated, said Dr. Michael Knudson, co-medical director of the DeGowin Blood Center at the University of Iowa Carver College of Medicine.

Knudson said his early research shows plasma from recovered then vaccinated people can provide five to 20 times more neutralizing antibody than the plasma from those who have not been vaccinated. “This would be almost a completely different product compared to what is used to date,” he wrote in a presentation to colleagues.

Joyner and others believe “boosted” plasma could be used as a potent antiviral treatment early in infection, similar to how monoclonal antibodies — laboratory-made proteins that act like human antibodies in the immune system — are used. It could be a cheaper option for low-resource countries unable to afford the monoclonal treatments at more than $1,200 per dose.

Even the National Institutes of Health scientists conducting the halted C3PO trial, Dr. Simone Glynn and Dr. Nahed El Kasser, agreed that more data about the usefulness of convalescent plasma is needed. “The answer is no, it is not the final word,” they said in an emailed statement.

But overcoming skepticism about the use of any type of convalescent plasma, let alone “super” plasma, won’t be easy, given the roller coaster of recent results. And broad use of convalescent plasma will depend on continued funding. If the federal contracts with blood collectors are not renewed, covid convalescent plasma likely will be paid for by hospitals or private insurers, depending on where patients receive the treatment.

In the meantime, the federal government, along with academic centers and private donors, has continued to fund the Hopkins and Vanderbilt trials. And the federal Biomedical Advanced Research and Development Authority has allocated at least $27 million to for-profit companies that collect covid convalescent plasma from paid donors to create hyperimmune globulin, a purified and concentrated form of plasma that may halt disease. Results from late-stage clinical trials of that therapy are expected later this spring.

“I think that it would be a mistake to stop now,” said Dr. Claudia Cohn, chief medical officer of the AABB, an international nonprofit focused on transfusion medicine and cellular therapies. “We have some evidence that it works and evidence that we can produce high-titer plasma. Let’s see what we can do to keep people out of the hospital.”

KHN (Kaiser Health News) is a national newsroom that produces in-depth journalism about health issues. Together with Policy Analysis and Polling, KHN is one of the three major operating programs at KFF (Kaiser Family Foundation). KFF is an endowed nonprofit organization providing information on health issues to the nation.

USE OUR CONTENT

This story can be republished for free (details).

Syndicated from https://khn.org/news/article/convalescent-plasma-covid-battle-super-donors/